Catalyst Pharmaceuticals is dedicated to developing innovative therapies for patients suffering from rare neurological and neuromuscular diseases. The company has successfully brought several FDA-approved products to market, including AGAMREE® (vamorolone), a novel corticosteroid designed to treat Duchenne muscular dystrophy (DMD), and FIRDAPSE® (amifampridine), which is indicated for Lambert-Eaton myasthenic syndrome (LEMS). These products exemplify Catalyst's commitment to addressing unmet medical needs through cutting-edge science and strategic partnerships, enhancing their ability to deliver transformative treatments to patients.

In addition to its current product offerings, Catalyst Pharmaceuticals actively pursues business development opportunities to expand its portfolio and geographic reach. The company has established collaborations with other pharmaceutical firms, such as BioMarin and Santhera Pharmaceuticals, to secure exclusive rights for the commercialization of their products in various regions. This strategic approach not only facilitates the growth of Catalyst's product pipeline but also reinforces its position as a leader in the rare disease sector, ensuring that innovative therapies reach the patients who need them most.

United States

Catalyst is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases.

Cancer

Genetic Diseases

Immune System Diseases

Musculoskeletal Diseases

Nervous System Diseases

Catalyst Pharmaceutical

Autoimmune disease

Lamber-Eaton myasthenic syndrome

<p class="font_7">Firdapse® (amifampridine) 10 mg tablets is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In turn, it induces the exocytosis of synaptic vesicles containing Acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission, and providing for improved muscle function.</p>

Catalyst Pharmaceutical

Company Details